NetworkNewsBreaks

WednesdayApr 12, 2017 10:39 am

NetworkNewsBreaks – Grey Cloak Tech, Inc. (GRCK) Completes Acquisition of ShareRails

Grey Cloak Tech, Inc. (OTC: GRCK) this morning announced the completion of its acquisition of ShareRails, a provider of online-to-offline (O2O) e-commerce services that is currently valued at more than $6.4 million by Excel Management Systems. “This is a great opportunity for Grey Cloak Tech,” Fred Covely, CEO of Grey Cloak Tech, stated in the news release. “Our entire management team spent a week in Hong Kong last month with the ShareRails development team. We met with the platform's existing clients, as well as developed new relationships, and recognize that the online-to-offline business opportunities are substantial in the southeast region…

Continue Reading

TuesdayApr 11, 2017 1:17 pm

NetworkNewsBreaks – Top 10 Mid-day Percentage Gainers on April 11, 2017

Here is a list of stocks shaking up the markets today, with particular focus on NASDAQ and OTC small caps. The top gainers based on percentage: WINT 18.95% – News: Reports completion of final interim safety review of AEROSURF® by Data Safety Monitoring Board RMGN 18.06% – News: Secures contract for second major supply chain customer roll-out in 2017 DTRM 12.05% – News: Determine cloud platform selected by Orion Corporation SNYR 11.11% – News: Launches The Synergy Effect AMMA 10.69% – News: Two alumni win at UFC 210 WTER 7.90% – News: Appoints new members to advisory board ARQL 5.45%…

Continue Reading

TuesdayApr 11, 2017 1:16 pm

NetworkNewsBreaks – Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) Meets Phase 1 Portion of Intratumoral IMO-2125 Combination Trial, Begins Enrolling Phase 2 Trial

Idera Pharmaceuticals (NASDAQ: IDRA) this morning announced the successful completion of the phase 1 portion of the ongoing phase 1/2 clinical trial of intratumoral IMO-2125 for the treatment of anti-PD-1 refractory metastatic melanoma. Enrollment has commenced for the phase 2 portion of the trial, and Idera expects to have overall response rate (ORR) data available in the first quarter of 2018. “There is a very clear unmet medical need for those patients for whom current checkpoint inhibitor therapies are not providing adequate solutions. We are incredibly focused on advancing this program as rapidly as possible for these patients, and we…

Continue Reading

TuesdayApr 11, 2017 11:47 am

NetworkNewsBreaks – Tonix Pharmaceuticals (NASDAQ: TNXP) Shares Rally on Results from U.S. FDA Meeting on TNX-102 SL for PTSD

Shares of Tonix Pharmaceuticals (NASDAQ: TNXP) are up 12% this morning on news that the company has received official minutes from its Initial Cross-Disciplinary Breakthrough Meeting held with the U.S. Food and Drug Administration (FDA) on March 9, 2017.  After being awarded Breakthrough Therapy designation in December 2016, Tonix was invited to meet with the FDA to evaluate the feasibility of accelerating the development and registration of TNX-102 SL for the treatment of posttraumatic stress disorder (PTSD). “The FDA’s standard of evidence for drug approval typically requires two positive Phase 3 trials; however, following our Initial Cross-Disciplinary Breakthrough Meeting in…

Continue Reading

TuesdayApr 11, 2017 10:05 am

NetworkNewsBreaks – Bollente Companies’ (BOLC) trutankless® Line Selected for Multiple Projects by Leading Senior Living Management Company

Bollente Companies, Inc. (OTCQB: BOLC) this morning announced that its innovative trutankless® line of smart water heaters has been selected for both a retrofit project and new construction of townhomes at Friendship Village, a retirement community located in Tempe, Arizona. The property is owned by Life Care Services Corporation, a leading senior living management and development company. “With its small footprint, energy savings and inherent longevity, trutankless is an ideal solution for the senior living industry which is expected to continue to outpace the overall economy,” Michael Stebbins of Bollente Companies stated in this morning’s news release. “Besides all the…

Continue Reading

TuesdayApr 11, 2017 9:40 am

NetworkNewsBreaks – CytoDyn Inc. (CYDY) Adds Dr. Scott A. Kelly to Board of Directors

Biotechnology company CytoDyn Inc. (OTCQB: CYDY) this morning announced the addition of Scott A. Kelly, M.D., FAAPMR, to its board of directors, effective April 10, 2017. With this appointment, the company’s board of directors now includes eight members. “Scott is passionate about target-specific treatments and personalized medicine that improve the lives of patients,” Denis R. Burger, Ph.D., vice chairman and chief science officer of CytoDyn, stated in the news release. “He has been a supporter and significant investor in CytoDyn, and we look forward to his contributions to our Company as a member of our Board.” Kelly brings considerable industry…

Continue Reading

MondayApr 10, 2017 12:55 pm

NetworkNewsBreaks – Top 10 Mid-day Percentage Gainers on April 10, 2017

Here is a list of stocks shaking up the markets today, with particular focus on NASDAQ and OTC small caps. The top gainers based on percentage: WSTL 9.61% – News: Presentation by CEO, CFO available online AKER 4.62% – News: Begins marketing Heparin PF4 Rapid Test in Puerto Rico ASPU 4.59% – News: Closes $7.5M common stock private placement PME 4.49% – News: Purchases five internationally licensed vessels ORIG 4.37% – News: Receives Nasdaq compliance notice PRQR 3.09% – News: Holding annual general meeting of shareholders on May 10 SHIP 2.86% – News: Adjusts pro-forma capitalization for certain material agreements…

Continue Reading

MondayApr 10, 2017 12:53 pm

NetworkNewsBreaks – Cemtrex, Inc. (NASDAQ: CETX) Shares Climb on Multi-Million Dollar Purchase Order, Expectations for Organic Growth

Cemtrex (NASDAQ: CETX) this morning said it has received a multi-million dollar order from HBH GmbH of Germany to build electronic components for high-power HF amplifiers for the FRIB particle accelerator at Michigan State University. The company expects to complete the order for the new customer over the next 18-month period. “We are excited to be working with HBH GmbH in supporting Michigan State University on this unique application. We believe that working on extremely complex high-tech electronics such as this validates our underlying strategy to focus on niche high-value markets. This strategy is expected to allow us to maintain…

Continue Reading

MondayApr 10, 2017 12:50 pm

NetworkNewsBreaks – Geron Corp. (NASDAQ: GERN) Shares Higher on Second Internal Data Reviews for Imetelstat Trials

Geron Corporation (NASDAQ: GERN) shares climbed 21% on news that the second internal data reviews of the company’s IMerge and IMbark clinical trials have been completed by Janssen Research & Development, LLC. IMerge, the study of the telomerase inhibitor imetelstat in lower risk myelodysplastic syndromes (MDS), demonstrated that the benefit/risk profile of imetelstat in the treated patients supports continued development. The company intends to provide the FDA with a data package and proposed trial design refinements. For IMbark, a study of imetelstat in relapsed or refractory myelofibrosis (MF), current data suggest clinical benefit and a potential overall survival benefit. The…

Continue Reading

MondayApr 10, 2017 12:13 pm

NetworkNewsBreaks – Cytori (NASDAQ: CYTX) Shares Surge on FDA Approval for RELIEF Trial Linked to BARDA Contract

Shares of Cytori Therapeutics (NASDAQ: CYTX) are up 34% in morning trade after the company said that the U.S. Food and Drug Administration (FDA) has approved an Investigational Device Exemption (IDE) for a pilot clinical trial to evaluate Cytori Cell Therapy™ in patients with thermal burn injury. The RELIEF trial continues the company’s ongoing research and development work under its contract with the Biomedical Advanced Research and Development Authority (BARDA), a division of the U.S. Department of Health and Human Services. The trial will assess safety and feasibility of intravenous delivery of Cytori Cell Therapy™ as an adjunct to usual…

Continue Reading